P O Witteveen1, J van der Velden2, I Vergote3, C Guerra4, C Scarabeli5, C Coens6, G Demonty6, N Reed7. 1. Department of Medical Oncology, University Medical Center Utrecht. Electronic address: P.O.Witteveen@umcutrecht.nl. 2. Department of Gynaecological Oncology, Academic Medical Center, Amsterdam, The Netherlands. 3. Department of Gynaecological Oncology, University Hospital Leuven, Belgium. 4. Department of Gynaecological Oncology, Hospitais da Universidade de Coimbra, Coimbra, Portugal. 5. Department of Gynecological Oncology, Azienda Ospedaliera di Pavia, Italy. 6. EORTC Headquarters, Brussels, Belgium. 7. Department of Clinical Oncology, Gartnavel General Hospital, Glasgow, UK.
Abstract
BACKGROUND: No standard treatment options are available for patients with advanced, recurrent or metastatic vulvar carcinoma not amenable for locoregional treatment. PATIENTS AND METHODS: In this phase II study, patients with advanced vulvar cancer received paclitaxel (Taxol) every 3 weeks for up to 10 cycles. Primary objective was response rate. Secondary objectives were response duration and toxicity. Response evaluation was assessed by World Health Organisation criteria, toxicity according to Common Toxicity Criteria. RESULTS: Thirty-one women from 10 institutions were included, with a median age of 64 (range 47-84), of which 29 were assessable for response. On study patients received a median of four cycles (range 1-10). SAFETY: Grade 3 and 4 neutropenia was seen in eight patients (8/29 = 27.6%), which in one patient resulted in neutropenic fever and treatment-related death. Further treatment-related grade 3/4 toxicity includes fatigue in three patients (10.3%) and neuropathy in one patient (3.4%). EFFICACY: Overall response was 13.8% (n = 4; two complete responses + two partial responses). With a median follow-up of 24 months, median PFS was 2.6 months (95%confidence interval 2.04-4.21). CONCLUSION: Paclitaxel shows moderate activity for local control in advanced vulvar cancer.
BACKGROUND: No standard treatment options are available for patients with advanced, recurrent or metastatic vulvar carcinoma not amenable for locoregional treatment. PATIENTS AND METHODS: In this phase II study, patients with advanced vulvar cancer received paclitaxel (Taxol) every 3 weeks for up to 10 cycles. Primary objective was response rate. Secondary objectives were response duration and toxicity. Response evaluation was assessed by World Health Organisation criteria, toxicity according to Common Toxicity Criteria. RESULTS: Thirty-one women from 10 institutions were included, with a median age of 64 (range 47-84), of which 29 were assessable for response. On study patients received a median of four cycles (range 1-10). SAFETY: Grade 3 and 4 neutropenia was seen in eight patients (8/29 = 27.6%), which in one patient resulted in neutropenic fever and treatment-related death. Further treatment-related grade 3/4 toxicity includes fatigue in three patients (10.3%) and neuropathy in one patient (3.4%). EFFICACY: Overall response was 13.8% (n = 4; two complete responses + two partial responses). With a median follow-up of 24 months, median PFS was 2.6 months (95%confidence interval 2.04-4.21). CONCLUSION:Paclitaxel shows moderate activity for local control in advanced vulvar cancer.
Authors: F Hinten; L C G van den Einden; J C M Hendriks; A G J van der Zee; J Bulten; L F A G Massuger; H P van de Nieuwenhof; J A de Hullu Journal: Br J Cancer Date: 2011-10-04 Impact factor: 7.640
Authors: Manavi Sachdeva; Natalie Y L Ngoi; Diana Lim; Michelle L M Poon; Yee Liang Thian; Yi Wan Lim; Siew Eng Lim; Pearl Tong; Jeffrey H Y Lum; Joseph Ng; Arunachalam Ilancheran; Efren J Domingo; Jeffrey J H Low; David S P Tan Journal: Onco Targets Ther Date: 2021-06-29 Impact factor: 4.147
Authors: Charles A Kunos; James Brindle; Steven Waggoner; Kristine Zanotti; Kimberly Resnick; Nancy Fusco; Ramon Adams; Robert Debernardo Journal: Front Oncol Date: 2012-12-05 Impact factor: 6.244